PFA-100 System: A New Method for Assessment of Platelet Dysfunction^[*]

 

 Buy Article Permissions and Reprints

Abstract

This is a celebratory reprint of a historical paper published in STH in 1998. The original Abstract follows.

The PFA-100 system is a platelet function analyzer designed to measure platelet-related primary hemostasis. The instrument uses two disposable cartridges: a collagen/epinephrine (CEPI) and a collagen/ADP (CADP) cartridge. Previous experience has shown that CEPI cartridges detect qualitative platelet defects, including acetylsalicylic acid (ASA)-induced abnormalities, while CADP cartridges detect only thrombocytopathies and not ASA use. In this seven-center trial, 206 healthy subjects and 176 persons with various platelet-related defects, including 127 ASA users, were studied. The platelet function status was determined by a platelet function test panel. Comparisons were made as to how well the defects were identified by the PFA-100 system and by platelet aggregometry. The reference intervals for both cartridges, testing the 206 healthy subjects, were similar to values described in smaller studies in the literature (mean closure time [CT] of 132 seconds for CEPI and 93 seconds for CADP). The use of different lot numbers of cartridges or duplicate versus singleton testing revealed no differences. Compared with the platelet function status, the PFA-100 system had a clinical sensitivity of 94.9% and a specificity of 88.8%. For aggregometry, a sensitivity of 94.3% and a specificity of 88.3% were obtained. These values are based on all 382 specimens. A separate analysis of sensitivity by type of platelet defect, ASA use versus congenital thrombocytopathies, revealed for the PFA-100 system a 94.5% sensitivity in identifying ASA users and a 95.9% sensitivity in identifying the other defects. For aggregometry, the values were 100% for ASA users and 79.6% for congenital defects. Analysis of concordance between the PFA-100 system and aggregometry revealed no difference in clinical sensitivity and specificity between the systems (p > 0.9999). The overall agreement was 87.5%, with a Kappa index of 0.751. The two tests are thus equivalent in their ability to identify normal and abnormal platelet defects. Testing 126 subjects who took 325 mg ASA revealed that the PFA-100 system (CEPI) was able to detect 71.7% of ASA-induced defects with a positive predictive value of 97.8%. The overall clinical accuracy of the system, calculated from the area under the receiver operating characteristic curve, was 0.977. The data suggest that the PFA-100 system is highly accurate in discriminating normal from abnormal platelet function. The ease of operation of the instrument makes it a useful tool to use in screening patients for platelet-related hemostasis defects.

^* This article is a republished version of: Mammen EF, Gosselin R, Greenberg C, Hoots WK, Kessler CM, Larkin EC, Liles D, Nugent DJ. PFA-100 system: a new method for assessment of platelet dysfunction. Semin Thromb Hemost 1998;24(02):195–202.

Publication History

Article published online:
13 December 2023

© 2023. Thieme. All rights reserved.

Thieme Medical Publishers, Inc.
333 Seventh Avenue, 18th Floor, New York, NY 10001, USA

• References

• 1 Majerus PW. Platelets. In: Stamatoyannapoulos G, Nienhuis AW, Majerus PW, Varmus H. eds. The Molecular Basis of Blood Diseases. Philadelphia, PA:: Saunders; 1994: 753-785
  Google Scholar
• 2 Kieffer N, Phillips DR. Platelet membrane glycoproteins: functions in cellular interactions. Annu Rev Cell Biol 1990; 6: 329-357
  CrossrefPubMedGoogle Scholar
• 3 Moncada S, Vane JR. Arachidonic acid metabolites and the interactions between platelets and blood-vessel walls. N Engl J Med 1979; 300 (20) 1142-1147
  CrossrefPubMedGoogle Scholar
• 4 Mielke CH. Measurement of the bleeding time. Thromb Haemost 1984; 52: 2l0-211
  PubMedGoogle Scholar
• 5 Rodgers RPC, Levin J. A critical reappraisal of the bleeding time. Semin Thromb Hemost 1990; 16 (01) 1-20
  Article in Thieme ConnectPubMedGoogle Scholar
• 6 De Caterina R, Lanza M, Manca G. et al. Bleeding time and bleeding: an analysis of the relationship of the bleeding time test with parameters of surgical bleeding. Blood 1994; 994 (84) 3363-3370
  CrossrefPubMedGoogle Scholar
• 7 MacDonald JD, Remington BJ, Rodgers GM. The skin bleeding time test as a predictor of brain bleeding time in a rat model. Thromb Res 1994; 76 (06) 535-540
  CrossrefPubMedGoogle Scholar
• 8 Born GVR. Aggregation of blood platelets by adenosine diphosphate and its reversal. Nature 1962; 194: 927-929
  CrossrefPubMedGoogle Scholar
• 9 Theroux P, Garcia-Dorado D. Antithrombotic therapy in chronic ischemic heart disease. In: Hull RD, Pineo GF. , eds: Disorders of Thrombosis. Philadelphia, PA: Saunders; 1996: 90-105
  Google Scholar
• 10 Alshameri RS, Mammen EF. Clinical experience with the Thrombostat 4000. Semin Thromb Hemost 1995; 21 (Suppl. 02) 1-10
  Article in Thieme ConnectPubMedGoogle Scholar
• 11 Kratzer MAA, Kretschmer V, Mammen EF. Advances in methods for platelet function analysis. Semin Thromb Hemost 1995; 21 (Suppl. 02) 1-121
  Article in Thieme ConnectPubMedGoogle Scholar
• 12 Mammen EF, Alshameeri RS, Comp PC. Preliminary data from a field trial of the PFA-100 system. Semin Thromb Hemost 1995; 21 (Suppl. 02) 113-121
  Article in Thieme ConnectPubMedGoogle Scholar
• 13 Kundu SK, Heilmann EJ, Sio R, Garcia C, Davidson RM, Ostgaard RA. Description of an in vitro platelet function analyzer–PFA-100. Semin Thromb Hemost 1995; 21 (02, Suppl 2): 106-112
  Article in Thieme ConnectPubMedGoogle Scholar
• 14 Document NCCLS. H28-T, vol 12, no 22,. Tentative Guideline Dec 1992
  PubMedGoogle Scholar
• 15 Document NCCLS. H29-T, vol 12, no 23,. Tentative Guideline Dec 1992
  PubMedGoogle Scholar
• 16 Kundu S, Heilmann EJ, Sio R. et al. Characterization of an in vitro platelet function analyzer, PFA-l00™. Clin Appl Thromb Hemost 1996; 2: 241-249
  CrossrefPubMedGoogle Scholar
• 17 Kundu S, Nicholson N, Salyers A. et al. In-vitro assessment of platelet inhibition with SC-54701 by PFA-100™. Thromb Haemost 1997; 78: 633
  PubMedGoogle Scholar
• 18 Heilmann EJ, Kundu SK, Sio R, Garcia C, Gomez R, Christie DJ. Comparison of four commercial citrate blood collection systems for platelet function analysis by the PFA-100 system. Thromb Res 1997; 87 (01) 159-164
  CrossrefPubMedGoogle Scholar
• 19 Wilmer M, Sio R, Kolde H-J, de Hann J. Characterization of preanalytical and technical variables when using the PFA-100™ test system. Ann Hematol 1997; 74 (02) 117
  PubMedGoogle Scholar
• 20 Carcao MD, Dean J, He L. et al. Evaluation of platelet function in a pediatric setting using the platelet function analyzer (PFA-100™). Thromb Haemost 1997; 78: 74 (Poster)
  PubMedGoogle Scholar
• 21 Fressinaud E, Veyradier A, Trossaert M. et al. Screening and control of therapy of patients with von Willebrand disease using a new analyzer of platelet function under high shear stress. Thromb Haemost 1997; 78: 696
  PubMedGoogle Scholar
• 22 Weippart-Kretschmer M, Miller A, Kretschmer V. Platelet function analyzer (PFA-I00™) for screening of von Willebrand's disease (vWD). Ann Haematol 1997; 74 (Suppl. 02) 118
  PubMedGoogle Scholar
• 23 Maier CM. PFA-100™ system: a sensitive screening test for platelet-related hemostasis defects. Ann Hematol 1997; 74 (02) 72
  PubMedGoogle Scholar
• 24 Bohner J, von Pape K-W, Wiebersinsky W. et al. Serial assessment of platelet function following a single 300 mg dose of acetylsalicylic acid. Ann Hematol 1997; 74 (02) 136
  PubMedGoogle Scholar
• 25 Borris M, Sohngen D, Englisch C. et al. Measurement of the effect of aspirin and ticlopidine on platelet function with a simple in vitro bleeding test. Ann Hematol 1997; 74 (02) 73
  PubMedGoogle Scholar